상세 보기
Ascend Phase 3 Study of Acalabrutinib vs Investigator's Choice of Rituximab Plus Idelalisib (IDR) or Bendamustine (BR) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
- Hebart, Holger;
- Ghia, Paolo;
- Jurczak, Wojciech;
- Pluta, Andrzej;
- Wach, Malgorzata;
- ... Lee, Jae Hoon;
- 외 15명
Citations
WEB OF SCIENCE
0- 제목
- Ascend Phase 3 Study of Acalabrutinib vs Investigator's Choice of Rituximab Plus Idelalisib (IDR) or Bendamustine (BR) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
- 저자
- Hebart, Holger; Ghia, Paolo; Jurczak, Wojciech; Pluta, Andrzej; Wach, Malgorzata; Lysak, Daniel; Kozak, Tomas; Simkovic, Martin; Kaplan, Polina; Kryachok, Irina; Illes, Arpad; De la Serna, Javier; Dolan, Sean; Campbell, Philip; Musuraca, Gerardo; Jacob, Abraham; Avery, Eric; Patel, Priti; Quah, Cheng; Liang, Wei; Lee, Jae Hoon
- 발행일
- 2020-02
- 유형
- Meeting Abstract
- 권
- 43
- 페이지
- 128 ~ 129
- 언어
- ENG
- 출판사
- KARGER
- 발행국가
- 스위스
- 분량
- 2 페이지
- ISSN
- E 2296-5262
P 2296-5270